Research Projects & Grants

For Profit Organization

  • Post-marketing requirement study to evaluate the safety of Octaplas™ versus plasma in patients undergoing orthotopic liver transplantation with special emphasis on hyperfibrinolysis, Role: Investigator, Octapharma, (06/2018 - 06/2019) Status: Completed
  • A 24 month, multicenter,randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in denovo renal transplant- advancing renal transplant efficacy and safety outcomes with an eveRolimus- based regimen (TRANSFORM, Jan 2015), Role: Investigator, Novartis Pharmaceuticals Corporation, (02/2018 - 02/2019) Status: Completed
  • A prospective observational trial to evaluate the correlation of T-SPOT® response to CMV infection and T cell-mediated acute graft rejection. The PROTECT Study (PROTECT, May 2015), Role: Investigator, Oxford Immunotec, (07/2017 - 07/2018) Status: Completed

Internal

  • The role of B cells in kidney allograft dysfunction (B cell 3/1/2014), Role: Investigator, LLU Transplantation Institute, (06/2022 - 06/2023) Status: Completed
  • Clinical outcomes of induction therapies in renal transplant patients, Role: Investigator, LLU Transplantation Institute, (12/2007 - 12/2015) Status: Completed

Non-Profit Organization

  • Characterization of Immune-editing Mechanisms in the Microenvironment of Hepatocellular Carcinoma, Role: Principal Investigator, Association for the Study of Liver Diseases, (05/2015 - 12/2016) Status: Closed
  • Inhibition of Circulating Osteopontin Inhibits Growth and Metastasis of Hepatocellular Cancer, Role: Principal Investigator, American College of Surgeons, (01/2015 - 03/2016) Status: Closed
  • Characterization of Immune-editing Mechanisms in the Microenvironment of Hepatocellular Carcinoma, Role: Principal Investigator, Central Surgical Association, (01/2015 - 12/2019) Status: Closed